ASP-3026

DB12729InvestigationalSmall molecule

ASP3026 has been used in trials studying the treatment of Solid Tumor, B-Cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, and Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS.

Mechanism: Pharmacologically active on ALK tyrosine kinase receptor
Curator reviewed
Formula / weight: C₂₉H₄₀N₈O₃S · 580.75 g/mol (avg)
Code names: ASP3026

Resolves to

Compound

UNIIHP4L6MXF10CAS1097917-15-1ChEMBLCHEMBL3545360PubChem25134326

Structure

InChIKeyMGGBYMDAPCCKCT-UHFFFAOYSA-NSMILESCOC1=CC(=CC=C1NC1=NC(NC2=CC=CC=C2S(=O)(=O)C(C)C)=NC=N1)N1CCC(CC1)N1CCN(C)CC1

Targets

Q9UM73ALK

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with ASP-3026, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account